Heart Disease Doesn't Start With Chest Pain

Understanding Cardiovascular Risk Beyond Symptoms

Cardiovascular disease remains the leading cause of mortality in the United States. It is commonly associated with acute symptoms such as chest pain or shortness of breath; however, in many individuals, the underlying disease process develops gradually and without symptoms over an extended period of time.

Routine clinical evaluations often include blood pressure measurement, standard lipid testing, and, in selected cases, functional testing such as exercise stress testing. When results fall within established reference ranges, these findings may be interpreted as reassuring. While appropriate and evidence-based, such evaluations do not always capture the full range of cardiovascular risk for every individual.

The Role and Limitations of Standard Testing

Cardiovascular disease does not arise from a single abnormal value. Rather, risk may accumulate over time and be influenced by multiple factors, including metabolic trends, family history, inflammatory markers, and genetic predisposition. Some commonly encountered clinical scenarios include:

• Lipid values within reference ranges accompanied by elevated atherogenic particle measures
• Glycemic markers that remain within normal limits but demonstrate gradual longitudinal change
• Normal functional testing that reflects current myocardial perfusion but does not assess atherosclerotic plaque burden
• Family history that suggests increased risk but does not meet strict diagnostic criteria
  
  

Individually, these findings may not warrant additional evaluation. In aggregate and over time, they may inform a more nuanced understanding of cardiovascular risk.

Interpreting Cardiovascular Risk Over Time

The prediction of cardiovascular events is most accurately informed by patterns rather than isolated data points. These patterns may include:

• Longitudinal trends across laboratory and clinical measures
• Early metabolic changes preceding established disease
• Risk markers not included in standard screening panels
• Individual variability in risk expression based on genetic and familial factors
  
  

Cardiovascular disease represents a biological process that may precede symptoms by many years. The absence of symptoms does not necessarily indicate the absence of disease, just as the presence of risk factors does not guarantee a clinical cardiac event.

Functional Testing and Symptom-based Evaluation

Functional studies such as stress testing are valuable tools for identifying certain forms of advanced coronary disease. They are not intended to detect early atherosclerosis or to predict future cardiovascular events in all populations. Appropriate test selection depends on clinical context, patient characteristics, and established guidelines.

A Prevention-focused Clinical Approach

Cardiovascular prevention is not defined by the volume of testing performed. It involves the thoughtful selection of evaluations based on individual risk, clinical history, and evolving evidence.

This approach may include:

• Expanded lipid and metabolic assessment when clinically appropriate.  As an example, for years we have used standard lipid panels as the baseline for assessing risk. But these panels show only the mass of lipids within atherogenic particles as LDL-C and non-HDL. This is different from measuring the actual number of atherogenic particles, through apo-B testing which is a better predictor of atherogencity, i.e the ability of a substance to promote the buildup of fatty deposits (plaque) in the arteries.  
• Consideration of family and personal history in risk stratification
• Review of longitudinal data rather than isolated results
• Early risk-reduction strategies, which may include lifestyle modification, pharmacologic therapy, or both, based on shared clinical decision-making

The PYCC Care Model

PYCC operates within a physician-led, longitudinal care framework that emphasizes individualized assessment. Our model allows for extended clinical encounters, detailed review of longitudinal data, and proactive discussions regarding cardiovascular risk and the latest guidance for testing and treatment when appropriate and all developed through shared decision-making. 

Summary

Cardiovascular disease does not uniformly present with symptoms in its early stages. Risk assessment is complex and individualized, and no single test or value is definitive. The evidence for new testing and treatments in cardiovascular health is always moving fast and its important to stay up to date

A longitudinal, personalized and context-driven approach to cardiovascular evaluation may also support earlier identification of risk and informed preventive strategies. Clinical decisions should always be made in partnership between you and your physician, guided by evidence, judgment, and individual circumstances.

​
The content provided is for general educational purposes and is not a substitute for personalized medical care.